1-(7-hydroxy-chroman-6-yl)-ethanone | 55736-70-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 1-(7-hydroxy-chroman-6-yl)-ethanone
• 英文别名: 1-(7-Hydroxy-chroman-6-yl)-aethanon；6-Acetyl-2,3-dihydro-7-hydroxy-4H(1) benzopyran；1-(7-Hydroxychroman-6-yl)ethanone；1-(7-hydroxy-3,4-dihydro-2H-chromen-6-yl)ethanone
• CAS: 55736-70-4
• 化学式: C₁₁H₁₂O₃
• 分子量: 192.214
• InChiKey: DGEYDTBYLIBXIG-UHFFFAOYSA-N

物化性质

• 熔点：
  93 °C(Solvent: Ligroine)
• 沸点：
  364.1±42.0 °C(Predicted)
• 密度：
  1.222±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(7-hydroxy-chroman-6-yl)-ethanone 在 盐酸 、 amalgamated zinc 作用下， 生成 (6-ethyl-chroman-7-yloxy)-acetic acid
  参考文献：
  名称：

  Naylor et al., Journal of the Chemical Society, 1958, p. 1190,1192

  摘要：

  DOI：
• 作为产物：
  描述：

  7-羟基-4-氧代苯并吡喃-2-羧酸 在 甲醇 、 三氯化铝 、 乙醇 、 镍 、 硝基苯 作用下， 生成 1-(7-hydroxy-chroman-6-yl)-ethanone
  参考文献：
  名称：

  Naylor et al., Journal of the Chemical Society, 1958, p. 1190,1192

  摘要：

  DOI：

文献信息

• [EN] QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION<br/>[FR] COMPOSÉ DE QUINOLONE ET AGENT PHARMACEUTIQUE
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2010064735A1

  公开（公告）日：2010-06-10

  The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the quinolone compound of the invention is represented by Formula (1): wherein: R1 represents hydrogen or the like; R2 represents hydrogen or the like; R3 represents substituted or unsubstituted phenyl or the like; R4 represents halogen or the like; R5 represents hydrogen or the like; R6 represents hydrogen or the like; and R7 represents hydrogen or the like.

  本发明提供了一种喹诺酮化合物，该化合物能够抑制帕金森病的慢性进展或保护多巴胺神经元免受疾病病因的影响，从而抑制神经功能障碍的进展，以便在延长给予L-多巴的时间的同时改善神经元功能；本发明的喹诺酮化合物由公式(1)表示：其中：R1代表氢等；R2代表氢等；R3代表取代或未取代的苯基等；R4代表卤素等；R5代表氢等；R6代表氢等；R7代表氢等。
• Tricyclic mono-chromone-2-carboxylic acids
  申请人：Fisons Limited

  公开号：US04159273A1

  公开（公告）日：1979-06-26

  There are described compounds of formula I, ##STR1## in which R.sub.3 represents hydrogen, or alkyl C 1 to 6, R.sub.5 represents hydrogen, hydroxy, alkoxy C 1 to 6, alkanoyloxy C 2 to 6, alkenyloxy C 2 to 6, nitro, -NR.sub.1 R.sub.2, halogen, alkyl C 1 to 6, hydroxy-alkyl C 1 to 6, or hydroxy-alkoxy C 1 to 6, An adjacent pair of X, Y and Z form a --(CH.sub.2).sub.4 --, --CH.dbd.CH--CH.dbd.CH--or --O(CH.sub.2).sub.3 --chain, each of the chains optionally being substituted by one or two C 1 to 6 alkyl groups, and the remaining substituent X or Z represents alkenyl C2 to 6 optionally substituted by phenyl; halogen; or alkyl C 1 to 9 optionally substituted by one or more of the groups hydroxy, halogen, carbonyl oxygen, phenyl, or alkoxy C 1 to 6, Or, when an adjacent pair of X, Y and Z form a chain substituted by one or two C 1 to 6 alkyl groups, the remaining substituent X or Z may be hydrogen, and R.sub.1 and R.sub.2, which may be the same or different, are each hydrogen or alkyl C 1 to 6, And pharmaceutically acceptable derivatives thereof. Processes for making the compounds and pharmaceutical, e.g. anti-allergic, compositions containing the compounds are also described.

  描述了化合物的化学式I，其中R.sub.3代表氢或烷基C 1至6，R.sub.5代表氢，羟基，烷氧基C 1至6，烷酰氧基C 2至6，烯酰氧基C 2至6，硝基，-NR.sub.1 R.sub.2，卤素，烷基C 1至6，羟基烷基C 1至6，或羟基烷氧基C 1至6，相邻的X、Y和Z形成一个--(CH.sub.2).sub.4--，--CH.dbd.CH--CH.dbd.CH--或--O(CH.sub.2).sub.3--链，每个链可选择地被一个或两个C 1至6烷基取代，其余的取代基X或Z代表烯基C2至6，可选择地被苯基；卤素；或烷基C 1至9，可选择地被羟基，卤素，羰基氧，苯基或烷氧基C 1至6中的一个或多个基团取代，或者，当相邻的X、Y和Z形成一个链，被一个或两个C 1至6烷基取代，其余的取代基X或Z可以是氢，R.sub.1和R.sub.2，可以相同也可以不同，分别是氢或烷基C 1至6，以及它们的药学上可接受的衍生物。还描述了制备这些化合物的方法和含有这些化合物的药物，例如抗过敏组合物。
• QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION
  申请人：Otsubo Kenji

  公开号：US20110269705A1

  公开（公告）日：2011-11-03

  The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the quinolone compound of the invention is represented by Formula (1): wherein: R 1 represents hydrogen or the like; R 2 represents hydrogen or the like; R 3 represents substituted or unsubstituted phenyl or the like; R 4 represents halogen or the like; R 5 represents hydrogen or the like; R 6 represents hydrogen or the like; and R 7 represents hydrogen or the like.

  本发明提供了一种喹诺酮化合物，用于抑制帕金森病的慢性进展或保护多巴胺神经元免受疾病病因的影响，从而抑制神经功能障碍的进展，延长L-多巴胺治疗之前的时间，并改善神经元功能；本发明的喹诺酮化合物由式（1）表示：其中：R1代表氢或类似物；R2代表氢或类似物；R3代表取代或未取代的苯基或类似物；R4代表卤素或类似物；R5代表氢或类似物；R6代表氢或类似物；R7代表氢或类似物。
• Quinolone compound and pharmaceutical composition
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US08304546B2

  公开（公告）日：2012-11-06

  The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the quinolone compound of the invention is represented by Formula (1): wherein: R1 represents hydrogen or the like; R2 represents hydrogen or the like; R3 represents substituted or unsubstituted phenyl or the like; R4 represents halogen or the like; R5 represents hydrogen or the like; R6 represents hydrogen or the like; and R7 represents hydrogen or the like.

  本发明提供了一种喹诺酮化合物，该化合物能够抑制帕金森病的慢性进展或保护多巴胺神经元免受疾病病因的影响，从而抑制神经功能障碍的进展，延长L-多巴胺治疗之前的时间，同时改善神经元功能；本发明的喹诺酮化合物由式（1）表示：其中：R1代表氢或类似物；R2代表氢或类似物；R3代表取代或未取代的苯基或类似物；R4代表卤素或类似物；R5代表氢或类似物；R6代表氢或类似物；R7代表氢或类似物。
• USRE045108E1
  申请人：——

  公开号：——

  公开（公告）日：——